A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)

NCT04442503 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Depression, Postpartum

Interventions

DRUG: SAGE-217
DRUG: Placebo

Sponsor

Biogen